TY - JOUR
T1 - Genome-wide association analysis of common genetic variants of resistant hypertension
AU - on behalf of eMERGE network
AU - El Rouby, Nihal
AU - McDonough, Caitrin W.
AU - Gong, Yan
AU - McClure, Leslie A.
AU - Mitchell, Braxton D.
AU - Horenstein, Richard B.
AU - Talbert, Robert L.
AU - Crawford, Dana C.
AU - Gitzendanner, Matthew A.
AU - Takahashi, Atsushi
AU - Tanaka, Toshihiro
AU - Kubo, Michiaki
AU - Pepine, Carl J.
AU - Cooper-DeHoff, Rhonda M.
AU - Benavente, Oscar R.
AU - Shuldiner, Alan R.
AU - Johnson, Julie A.
N1 - Funding Information:
Funding INVEST was supported by grants from the University of Florida Opportunity Fund and Abbott Pharmaceuticals. INVEST-GENES was supported by NIH grants U01-GM074492, NIH R01 HL074730. The SPS3 trial was funded by the National Institute of Health and Neurological Disorders and Stroke Grant No. U01NS38529-04A1. The SPS3-GENES was funded by R01 NS073346 and U01-GM074492-05S109. Dr. El Rouby is supported by NIH grant T32HL083810 and Dr. McDonough is supported by NIH Grant 1 KL2 TR001429. The eMERGE Network is funded by NHGRI, with additional funding from NIGMS through the following grants: U01HG04599 and U01HG006379 to Mayo Clinic; U01HG004610 and U01HG006375 to Group Health Cooperative and University of Washington, Seattle; U01HG004608 to Marshfield Clinic; U01HG006389 to Essentia Institute of Rural Health; U01HG004609 and U01HG006388 to Northwestern University; U01HG04603 and U01HG006378 to Vanderbilt University; U01HG006385 to the Coordinating Center; U01HG006382 to Gei-singer Clinic; U01HG006380 to Mount Sinai School of Medicine. A portion of the dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center’s BioVU, supported by institutional funding and by the Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH, and the Mayo Clinic Biobank supported by the Mayo Clinic Center for Individualized Medicine.
Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Resistant hypertension (RHTN), defined as uncontrolled blood pressure (BP) ≥ 140/90 using three or more drugs or controlled BP (<140/90) using four or more drugs, is associated with adverse outcomes, including decline in kidney function. We conducted a genome-wide association analysis in 1194 White and Hispanic participants with hypertension and coronary artery disease from the INternational VErapamil-SR Trandolapril STudy—GENEtic Substudy (INVEST-GENES). Top variants associated with RHTN at p < 10−4 were tested for replication in 585 White and Hispanic participants with hypertension and subcortical strokes from the Secondary Prevention of Subcortical Strokes GENEtic Substudy (SPS3-GENES). A genetic risk score for RHTN was created by summing the risk alleles of replicated RHTN signals. rs11749255 in MSX2 was associated with RHTN in INVEST (odds ratio (OR) (95% CI) = 1.50 (1.2–1.8), p = 7.3 × 10−5) and replicated in SPS3 (OR = 2.0 (1.4–2.8), p = 4.3 × 10−5), with genome-wide significance in meta-analysis (OR = 1.60 (1.3–1.9), p = 3.8 × 10−8). Other replicated signals were in IFLTD1 and PTPRD. IFLTD1 rs6487504 was associated with RHTN in INVEST (OR = 1.90 (1.4–2.5), p = 1.1 × 10−5) and SPS3 (OR = 1.70 (1.2–2.5), p = 4 × 10−3). PTPRD rs324498, a previously reported RHTN signal, was among the top signals in INVEST (OR = 1.60 (1.3–2.0), p = 3.4 × 10−5) and replicated in SPS3 (OR = 1.60 (1.1–2.4), one-sided p = 0.005). Participants with the highest number of risk alleles were at increased risk of RHTN compared to participants with a lower number (p-trend = 1.8 × 10−15). Overall, we identified and replicated associations with RHTN in the MSX2, IFLTD1, and PTPRD regions, and combined these associations to create a genetic risk score.
AB - Resistant hypertension (RHTN), defined as uncontrolled blood pressure (BP) ≥ 140/90 using three or more drugs or controlled BP (<140/90) using four or more drugs, is associated with adverse outcomes, including decline in kidney function. We conducted a genome-wide association analysis in 1194 White and Hispanic participants with hypertension and coronary artery disease from the INternational VErapamil-SR Trandolapril STudy—GENEtic Substudy (INVEST-GENES). Top variants associated with RHTN at p < 10−4 were tested for replication in 585 White and Hispanic participants with hypertension and subcortical strokes from the Secondary Prevention of Subcortical Strokes GENEtic Substudy (SPS3-GENES). A genetic risk score for RHTN was created by summing the risk alleles of replicated RHTN signals. rs11749255 in MSX2 was associated with RHTN in INVEST (odds ratio (OR) (95% CI) = 1.50 (1.2–1.8), p = 7.3 × 10−5) and replicated in SPS3 (OR = 2.0 (1.4–2.8), p = 4.3 × 10−5), with genome-wide significance in meta-analysis (OR = 1.60 (1.3–1.9), p = 3.8 × 10−8). Other replicated signals were in IFLTD1 and PTPRD. IFLTD1 rs6487504 was associated with RHTN in INVEST (OR = 1.90 (1.4–2.5), p = 1.1 × 10−5) and SPS3 (OR = 1.70 (1.2–2.5), p = 4 × 10−3). PTPRD rs324498, a previously reported RHTN signal, was among the top signals in INVEST (OR = 1.60 (1.3–2.0), p = 3.4 × 10−5) and replicated in SPS3 (OR = 1.60 (1.1–2.4), one-sided p = 0.005). Participants with the highest number of risk alleles were at increased risk of RHTN compared to participants with a lower number (p-trend = 1.8 × 10−15). Overall, we identified and replicated associations with RHTN in the MSX2, IFLTD1, and PTPRD regions, and combined these associations to create a genetic risk score.
UR - http://www.scopus.com/inward/record.url?scp=85053779227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053779227&partnerID=8YFLogxK
U2 - 10.1038/s41397-018-0049-x
DO - 10.1038/s41397-018-0049-x
M3 - Article
C2 - 30237584
AN - SCOPUS:85053779227
SN - 1470-269X
VL - 19
SP - 295
EP - 304
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
IS - 3
ER -